Silo Pharma, Inc.: enters asset purchase agreement with Norsight Consulting

What happened Silo Pharma, Inc. announced that on Oct 1, 2026 it entered into an asset purchase agreement with Norsight Consulting Inc. Pursuant to the agreement, the company agreed to purchase certain software, technology and related intellectual property (the "Purchased Assets"), and issued a warrant to Norsight to purchase up to 300,000 shares of the company’s common stock.

Key details

• The common stock purchase warrant covers up to 300,000 shares, has an exercise price of $1.51 per share, includes a cashless exercise feature, is exercisable beginning Apr 1, 2027 and expires Sep 30, 2031.
• Norsight may not exercise the warrant to the extent it would own more than 4.99% of outstanding common stock immediately after exercise; that percentage may be increased or decreased but may not exceed 9.99% and any increase requires at least 61 days’ prior notice.
• Each share received by Norsight, including shares issuable upon exercise of the warrant, is subject to a lock-up starting on the effective date and ending on the earlier of (i) 12 months after such date, (ii) a change in control, or (iii) written consent of the company.
• The agreement contains customary representations, warranties and covenants, and Norsight agreed to indemnify the company for misrepresentations, breaches, infringement of third-party rights in the purchased assets and acts of gross negligence, fraud or intentional misconduct.

Why it may matter This Form 8-K reports Item 1.01 (entry into a material definitive agreement) and Item 3.02 (unregistered sales of equity securities) relating to the asset purchase and issuance of the warrant. This filing does not show why the insider traded or why the company acted.